HFrEF treatment — Research & Evidence

Q: What does the research say about HFrEF treatment?

The scientific consensus on HFrEF treatment is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Q: What do clinical guidelines recommend for HFrEF treatment?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What does the research say about HFrEF treatment?

Emerging pathwayBased on 100 claims (0 agreements, 0 contradictions)

Emerging evidence with 100 primary claims

Journal clubs discussing HFrEF treatment

Recent sessions

Inflammatory Hypothesis of CAD

STEMI Management — Wed, Aug 12, 8:00 AM EDT — 7 attended

Tri.Fr: The Heart of the Matter

OPCI Journal Club — Fri, Aug 7, 12:00 PM EDT

Cardiac intense unit demo

Cornell - Precision Medicine — Thu, Jul 23, 2:15 PM EDT

New data on Heart Failure Intervention

Synapse Team — Thu, Jul 16, 4:00 PM EDT

Frontiers in Precision Medicine Journal Club | Opening Session

Cornell - Precision Medicine — Fri, Jul 3, 12:00 PM EDT — 1 attended

GLP 1 new data

U Miami Journal Club — Thu, Jun 18, 2:00 PM EDT — 1 attended

Sessions from public journal clubs on Synapse. RSVP to join the live discussion.

New research on HFrEF treatment

Cardiac resynchronisation therapy for reversal of new-onset left bundle branch block and heart failure after surgical aortic valve replacement

BMJ Case Reports — Kalsi M — Dec 2020

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF

Journal of the American Heart Association — Fudim M — Dec 2020

Extracardiac Abnormalities of Preload Reserve

Circulation Heart Failure — Fudim M — Jan 2021

Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial

European Journal of Heart Failure — Málek F — May 2021

High Density Lipoprotein Cholesterol / C Reactive Protein Ratio in Heart Failure with Preserved Ejection Fraction

Stay current on HFrEF treatment

Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.

Journal Club takes on HFrEF treatment

Evidence brief: HFrEF treatment

HFrEF treatment (also known as HFrEF, systolic heart failure, reduced EF heart failure). Heart failure with reduced ejection fraction therapies

As of 2026-08-15, the scientific consensus on HFrEF treatment is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on HFrEF treatment. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hfref-treatment.

Deterministic synthesis from Synapse's enriched corpus — 206 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for HFrEF treatment?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Follow the latest HFrEF treatment research

Explore every HFrEF treatment paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search HFrEF treatment papers